Skip Navigation

European Heart Journal 1992 13(9):1251-1258;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias

ANTTARRHYTHMIC DRUG EVALUATION GROUP (A.D.E.G.)

Received 2 May 1991; revised 27 September 1991; .

Correspondence Roberto Latini, MD, Istituto Mario Negri, Via Eritrea 62, 20157 Milano, Italy

Abstract

The long-term benefit/risk profiles of amiodarone, flecainide and propafenone were compared in 141 patients with complex ventricular arrhythmias and cardiac disease, in a trial designed to mimic the clinical decision-making process. The patients were randomized to various sequences of the three drugs, at two dose levels andfollowedfor 2 years. Drug or doses were changed to deal with insufficient reduction of arrhythmias at 24 h ECG or severe adverse drug reaction (ADR). At 2 years 18 patients haddied (9/18 suddenly), 19 had withdrawn because of major clinical events or severe ADR, 13 had dropped out, seven hadbeen non-responders throughout the entire sequence of drugs, whereas eight were non-responders only at the last visit. Thus, 76 patients (54%) were responders after 2 years. Of these, 57 were responders for 2 years with thefirst drug. Median exposure time to amiodarone, 518 days . patienr', was higher than for flecainide and propafenone, 218 and 178, respectively, indicating better overall response to amiodarone (P<001). A total of50 ADRs led to drug with-drawal, with cardiovascular ADR being less frequent (P<003) for amiodarone (2/11) than for flecainide (13/16) and propafenone (16/23). In conclusion, with sequences of amiodarone, flecainide and propafenone, an overall response rate of 79% couldbe obtainedin theshort-term (7–28 days) and54% at 2years. Amiodarone has a morefavourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heartfailure.

Key Words: Antiarrhythmic drugs • ventricular arrhythmias • amiodarone • flecainide • propafenone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
I. Sim, K. M. McDonald, P. W. Lavori, C. M. Norbutas, and M. A. Hlatky
Quantitative Overview of Randomized Trials of Amiodarone to Prevent Sudden Cardiac Death
Circulation, November 4, 1997; 96(9): 2823 - 2829.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.